{"DataElement":{"publicId":"4040234","version":"1","preferredName":"Person Platinum Compound Chemotherapy Regimen Recurrent Disease Disease Progression Clinical Trial Eligibility Criteria Platinum-Based Chemotherapy Discontinue Recurrent Disease Duration","preferredDefinition":"information related the period of time during which return of a disease occured following the stop or end of platinum-based synthetic or naturally-occurring chemical-based agents to treat cancer as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3192319v1.0_Plat_C","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"3192321","version":"1","preferredName":"Person Platinum Compound Chemotherapy Regimen Recurrent Disease Disease Progression Clinical Trial Eligibility Criteria","preferredDefinition":"information related to disease recurrence and/or progression following platinum-based chemotherapy regimen as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3192319v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3192319","version":"1","preferredName":"Platinum Compound Chemotherapy Regimen Recurrent Disease Disease Progression Clinical Trial Eligibility Criteria","preferredDefinition":"Inorganic compounds which contain platinum as the central atom.:Drug therapy using two or more drugs given together or separately for a combined effect.:the return of a sign, symptom, or disease after a remission.:Cancer that continues to grow or spread.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3192319v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Platinum Compound","conceptCode":"C1450","definition":"A chemotherapy compound that contains a platinum atom. Platinum compounds do not contain alkyl groups but do cause DNA crosslinks and adducts similar to alkylating agents. DNA crosslinks and adducts ultimately lead to the induction of apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Chemotherapy Regimen or Agent Combination","conceptCode":"C12218","definition":"A combination of multiple drugs used in standard or clinical trial treatments. The order, dosage or dosing interval of the individual ingredients may not be specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C6AF356-ABA4-ED73-E040-BB89AD4338FB","latestVersionIndicator":"Yes","beginDate":"2011-02-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-16","modifiedBy":"ONEDATA","dateModified":"2011-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C6AF356-ABB5-ED73-E040-BB89AD4338FB","latestVersionIndicator":"Yes","beginDate":"2011-02-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-16","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4040232","version":"1","preferredName":"Platinum-Based Chemotherapy Discontinue Recurrent Disease Duration","preferredDefinition":"The period of time during which return of a disease occured following the stop or end of platinum-based synthetic or naturally-occurring chemical-based agents to treat cancer.","longName":"Plat_Chem_Disc_Recu_Dura","context":"NRG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"greater than 12 months","valueDescription":"Greater than 12 months","ValueMeaning":{"publicId":"2764414","version":"1","preferredName":"Greater than 12 months","longName":"2764414","preferredDefinition":"Greater than 12 months","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"519D3646-F849-55E0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EF14F6BF-292D-4FD6-E040-BB89AD431B8B","beginDate":"2014-01-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-03","modifiedBy":"ONEDATA","dateModified":"2014-01-03","deletedIndicator":"No"},{"value":"between 6 and 12 months","valueDescription":"between 6 and 12 months","ValueMeaning":{"publicId":"4040233","version":"1","preferredName":"between 6 and 12 months","longName":"4040233","preferredDefinition":"between 6 and 12 months","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF14F6BF-2937-4FD6-E040-BB89AD431B8B","latestVersionIndicator":"Yes","beginDate":"2014-01-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EF14F6BF-2950-4FD6-E040-BB89AD431B8B","beginDate":"2014-01-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-03","modifiedBy":"ONEDATA","dateModified":"2014-01-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4040231","version":"1","preferredName":"Platinum-Based Chemotherapy Discontinue Recurrent Disease Duration","preferredDefinition":"Derived from or containing platinum.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term is used to describe any therapy involving the use of chemical-based agents, it is particularly used to refer to the use of chemical-based agents to treat cancer. Antineoplastic chemotherapy works by arresting or killing the growth and spread of cancer cells. Chemotherapy may also include agents that enhance immune function or alter hormonal activity.:To stop or end, permanently or temporarily.:The return of a disease after a period of remission.:The period of time during which something continues.","longName":"4040231v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Platinum-Based","conceptCode":"C25620","definition":"Derived from or containing platinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Duration","conceptCode":"C25330","definition":"The period of time during which something continues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF14F6BF-28FF-4FD6-E040-BB89AD431B8B","latestVersionIndicator":"Yes","beginDate":"2014-01-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-03","modifiedBy":"ONEDATA","dateModified":"2014-01-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF14F6BF-2910-4FD6-E040-BB89AD431B8B","latestVersionIndicator":"Yes","beginDate":"2014-01-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-03","modifiedBy":"REBOYJ","dateModified":"2014-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000287","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"4104909","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"10000288","version":"1","longName":"GOG-0213","context":"NRG"}]}],"AlternateNames":[{"name":"2236731v1.0:3192319v1.0_Plat_C","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Is the time from completing f","type":"Preferred Question Text","description":"Is the time from completing first-line chemotherapy to registration on this study (i.e. treatment-free interval):","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF14F6BF-295A-4FD6-E040-BB89AD431B8B","latestVersionIndicator":"Yes","beginDate":"2014-01-03","endDate":null,"createdBy":"REBOYJ","dateCreated":"2014-01-03","modifiedBy":"FORMBUILDER","dateModified":"2014-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}